New groups of hypolipidemic drugs based on inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). Part 1

The hypolipidemic therapy is one of the essential components for the management of patients with cardiovascular diseases (CVD). In this regard, the main task of modern research is to find new targets for creating additional effective groups of lipid-lowering drugs. In 2003, a Canadian and French res...

Full description

Bibliographic Details

Published in:	Наука и инновации в медицине
Main Authors:	Aleksey M. Chaulin, Nikolay A. Svechkov, Dmitry V. Duplyakov
Format:	Article
Language:	English
Published:	Samara State Medical University 2021-03-01
Subjects:	cardiovascular diseases lipid-lowering drugs protein convertase subtilisin-kexin new type 9 proprotein convertase inhibitors subtilisin-kexin type 9 alirocumab evolocumab incliciran
Online Access:	https://innoscience.ru/2500-1388/article/viewFile/52647/pdf